Innovative Tri-Specific Nanobody Targeting ALB and CD3 Complex for Colorectal Cancer Immunotherapy
VHH-P471 is a next-generation, fully humanized nanobody specifically designed to engage albumin (ALB) and the CD3 Complex (T Cell Receptor Complex), currently under biological testing. Leveraging a tri-specific architecture, VHH-P471 is positioned as a promising therapeutic agent for colorectal cancer. It incorporates distinct variable regions that bind ALB and CD3, exploiting these clinically relevant targets for dual engagement of tumor cells and the immune system. The design enhances tumor localization and immune activation, aiming to address the significant unmet need in colorectal cancer therapy.
| Candidate | VHH-P471 |
| Target | albumin (ALB) CD3 Complex (T Cell Receptor Complex) |
| Modality | humanized bispecific VHH |
| Indication | Colorectal Cancer |
Licensing Opportunity
VHH-P471 is currently available for licensing and collaborative development. We welcome inquiries from partners seeking to co-develop or commercialize this tri-specific nanobody platform for innovative colorectal cancer therapies.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P471 |
Modality
VHH-P471 utilizes a tri-specific nanobody format, composed of three polypeptide chains linking variable regions against CEA, ALB, and CD3, along with human IgG1 constant regions for enhanced stability and half-life. Its modular design includes robust peptide linkers and distinctive knob-into-hole technology, facilitating precise assembly and trivalent binding. The nanobody’s small molecular weight and single-domain structure ensure excellent tumor tissue penetration and rapid pharmacokinetics, which are particularly advantageous in the context of solid tumor treatment such as colorectal cancer. The structural modularity and intrinsic stability of this nanobody format contribute to improved manufacturability and therapeutic versatility.
Target
VHH-P471 is engineered to target both ALB and CD3 Complex. ALB, a highly prevalent plasma protein, plays critical roles in drug transport and circulatory half-life extension, making it a valuable pharmaceutical target to increase antibody exposure and retention. CD3 Complex is a pivotal molecule in T cell signaling and activation, predominantly expressed on T lymphocytes; its engagement enables the specific redirection of immune effector cells to malignant tissue. By co-targeting ALB and CD3 Complex, VHH-P471 harnesses the extended exposure benefits of ALB and the powerful immunomodulatory effects mediated through CD3 Complex. The strategic selection of ALB and CD3 Complex creates a unique dual mechanism that supports optimized trafficking, immune synapse formation, and sustained anti-tumor activity in colorectal cancer, adding significant strategic value to VHH-P471's clinical development.
Mechanism of Action
VHH-P471 exerts its activity by simultaneously binding to ALB and CD3 Complex through its tri-specific nanobody scaffold. The anti-ALB domain confers prolonged systemic exposure by binding to circulating albumin, improving pharmacokinetic properties and tissue distribution. Engagement of CD3 Complex on T cells triggers their activation and redirection towards tumor cells displaying CEA. This dual-targeting facilitates the formation of an immunological synapse, leading to T cell-mediated cytotoxicity against colorectal cancer cells. Furthermore, the nanobody's modular architecture allows for future derivatizations, such as antibody-drug conjugates or bispecific formats, paving the way for expanded therapeutic applications in oncology and beyond.
Colorectal Cancer
Colorectal cancer is one of the most prevalent malignancies worldwide, significantly contributing to cancer morbidity and mortality. The disease often arises from precursor lesions in the colon or rectum and is associated with dietary, genetic, and environmental risk factors. Standard treatments currently include surgery, radiation, cytotoxic chemotherapy, and targeted therapies such as monoclonal antibodies and small molecule inhibitors. However, significant clinical challenges remain, such as disease recurrence, resistance to standard agents, and limited responses in advanced or metastatic cases. Immunotherapy has shown promise, yet response rates are modest for the majority of patients. There is a pressing need for novel immunotherapeutic agents that effectively mobilize the immune system with enhanced specificity and reduced toxicity. VHH-P471 offers substantial therapeutic potential in this indication by combining improved pharmacokinetics, immune redirection, and high tissue penetration—features directly addressing current unmet needs in colorectal cancer management.